The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.

ABSTRACT: Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival du

SUBMITTER: Mascarenhas JO 

PROVIDER: S-EPMC9324085 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature